Comparative Pharmacology
Head-to-head clinical analysis: CYCLOSET versus LYUMJEV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLOSET versus LYUMJEV.
CYCLOSET vs LYUMJEV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cycloset (bromocriptine mesylate) is a dopamine D2 receptor agonist. It improves glycemic control in type 2 diabetes by resetting hypothalamic circadian rhythms, thereby reducing hepatic glucose production and increasing insulin sensitivity. It also suppresses the release of very low-density lipoprotein from the liver.
LYUMJEV (insulin lispro-aabc) is a rapid-acting insulin analog that binds to the insulin receptor (IR), activating the IR tyrosine kinase cascade. This leads to increased glucose uptake in peripheral tissues (primarily skeletal muscle and adipose tissue), inhibition of hepatic gluconeogenesis, and promotion of glycogen synthesis. The aabc amino acid substitution (insulin lispro with proline at B28 replaced by lysine and lysine at B29 replaced by proline, plus an additional modification) results in faster dissociation from the insulin receptor and accelerated absorption from subcutaneous tissue compared to regular human insulin.
1.6 mg to 2.4 mg administered orally once daily at bedtime. Titrate by 0.8 mg every 2 weeks based on glycemic response and tolerability.
Subcutaneous injection at mealtime (within 15 minutes before or immediately after meal). Doses individualized; typical range 0.2-1.0 units/kg/day.
None Documented
None Documented
Terminal elimination half-life is 4–6 hours in patients with normal renal function; clinically, steady-state is reached within 24 hours.
Terminal elimination half-life of LYUMJEV (insulin lispro) is approximately 13.7 minutes (0.23 hours) in healthy subjects, reflecting rapid clearance from the bloodstream.
Renal: ~90% (30% unchanged, rest as inactive metabolites); fecal: ~10%.
Primarily renal; approximately 90% of absorbed dose is excreted via urine as metabolites and unchanged drug, with the remainder eliminated in feces (<10%).
Category C
Category C
Dopamine Agonist / Antidiabetic
Antidiabetic